Viking Therapeutics received positive results from its MAD trial, noting that the company benefits from Trump tariffs and onshoring policies.
2 reports, 1 independent
Updated Sep 22
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics received positive results from its MAD trial, noting that the company benefits from Trump tariffs and onshoring policies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
-
MAD
programming language and compiler
Nothing else this week.
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
- The Trump administration is currently negotiating tariffs.
- Trump's tariffs were ruled illegal by a federal court.
- Trump's tariff plan caused markets to tank, affecting company Flo.
Coverage
Newest first; wire copies grouped- Insider MonkeyViking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of These 10 Stocks Are Making Big Moves. Viking Therapeutics jumped by 9